Dermime Said, Aljurf Mahmoud D
Tumor Immunology Section, Department of Biological & Medical Research, King Faisal Specialist Hospital & Research Center, Riyadh, 11211, Saudi Arabia.
Leuk Lymphoma. 2005 Apr;46(4):497-507. doi: 10.1080/104281904000025104.
Despite advances in chemotherapy, radiotherapy and combined modality treatment, a significant proportion of non-Hodgkin's lymphomas remain incurable. The disease usually responds well to chemotherapy or radiation, but relapses are observed within months to a few years, with frequent failure of subsequent therapies. High-dose chemotherapy with or without radiation and autologous or allogeneic hematopoietic stem cell transplantation provide higher cure rates and longer remissions in certain patients with aggressive lymphomas. However, the higher treatment-related morbidity and mortality of high-dose chemotherapy has driven a search for new and more tumor-specific treatment modalities, such as immunotherapy. Tumor antigens expressed by B-cell lymphomas, such as the "idiotype antigen", are seen as unique and specific target molecules for direct lymphoma immunotherapy. This review will delineate advances, problems and prospects for approaches to anti-B cell lymphoma immunotherapy where pre-clinical studies and proof of principle have been directly translated to patient care.
尽管在化疗、放疗及综合治疗方面取得了进展，但仍有相当一部分非霍奇金淋巴瘤无法治愈。该疾病通常对化疗或放疗反应良好，但在数月至数年内会出现复发，后续治疗也常常失败。对于某些侵袭性淋巴瘤患者，采用含或不含放疗的大剂量化疗以及自体或异基因造血干细胞移植可提高治愈率并延长缓解期。然而，大剂量化疗较高的治疗相关发病率和死亡率促使人们寻找新的、更具肿瘤特异性的治疗方式，如免疫疗法。B细胞淋巴瘤表达的肿瘤抗原，如“独特型抗原”，被视为直接进行淋巴瘤免疫治疗的独特且特异性的靶分子。本综述将阐述抗B细胞淋巴瘤免疫治疗方法的进展、问题及前景，其中临床前研究和原理验证已直接应用于患者治疗。
